Compare Axon Enterprise Inc (AXON) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axon Enterprise Inc vs BridgeBio Pharma Inc — how do they compare? Axon Enterprise Inc trades at $634.17 (market cap $48.44B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: Axon Enterprise Inc is far larger — about 2.9× BridgeBio Pharma Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Axon Enterprise Inc nearer its low. Which is the better fit depends on your goals.
| AXON | BBIO | |
|---|---|---|
Market Cap | $48.44B | $16.61B |
Sector | Technology | Health |
52-Week High | $791.62 | $90.17 |
52-Week Low | $345.94 | $47.29 |
Enterprise Value | $49.59B | $18.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Axon Enterprise (AXON) trades at $571.01, up 9.29% with strong momentum following Q2 2026 results showing 35% revenue growth and 10 consecutive quarters above 30% expansion. Technical indicators show bullish moving averages with current price near resistance at $587. The company maintains dominant positioning in public safety technology with accelerating AI and counter-drone business segments driving future growth potential.
Axon presents compelling growth prospects with raised 2026 revenue guidance of 32-34% and expanding software ecosystem, though elevated valuations (P/E 248) and margin pressures from service mix shifts warrant caution. Analyst consensus remains strongly bullish with $685 price target representing 20% upside potential from current levels.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Axon Enterprise Inc
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
